卵巢恶性肿瘤患者血清可溶性细胞间粘附分子-1的检测及临床价值

Detection of serum sICAM-1 in patients with malignant ovarian tumor and its clinical value

目的检测卵巢恶性肿瘤患者血清可溶性细胞问粘附分子-1(sICAM-1)并分析其临床价值。方法采用双抗体夹心 ELISA 法检测54例卵巢恶性肿瘤患者 sICAM-1,并与对照组及其与临床分期之间的关系进行分析。结果 54例卵巢恶性肿瘤患者的 sICAM-1含量明显高于对照组(P<0.01);卵巢恶性肿瘤晚期(Ⅲ～Ⅳ)患者 sICAM-1含量也高于早期(Ⅰ～Ⅱ)患者,均有显著性差异(P<0.05)。结论卵巢恶性肿瘤患者血清 sICAM-1含量随着肿瘤恶化程度的增加而上升,sICAM-1有可能作为预测卵巢恶性肿瘤患者转归的一个指标。

Objective To investigate soluble intercellular adhesion molecule-1(sICAM-1) and analyse its clinical value.Methods Double antibody sandwich ELISA method was applied to examine serum sICAM-1 in 54 patients with malignant ovarian tumor while the relationship between sICAM-1 and the clinical stages was studied.Results The concentrations of serum sICAM-1 in 54 cases with malignant ovarian tumors were higher obviously than the control group(P<0.01),the serum sICAM- 1 with malignant ovavian tumors at late stages(Ⅲ～Ⅳ) was higher obviously than that at early stages (Ⅰ～Ⅱ)(P<0.05).Conclusion Serum sICAM-1 may be used as a marker for monitoring the prog- nosis of ovarian carcinomae.